London -- (MARKET WIRE) -- May 11, 2007 --
Curidium Medica plc ("Curidium" or the "Company")
CURIDIUM TO PRESENT AT RODMAN & RENSHAW 4th ANNUAL GLOBAL HEALTHCARE
CONFERENCE
- Presentation to be Webcast Live -
London, UK, 10 May, 2007, Curidium Medica plc, (LSE: CUR) today announced
that it will be presenting at the Rodman & Renshaw 4th Annual Global
Healthcare Conference in Monte Carlo, Monaco. Dr Anne Bruinvels, Chief
Executive Officer, will be presenting the current status of the Company
and its strategic business objectives. The presentation is scheduled at
5.00 pm local time on May 14th in the Meridian Beach Plaza Hotel. The
presentation will be webcast and accessible remotely by persons wishing
to follow the presentation live and will be archived for 30 days on the
Company's website; for access please visit:
www.rodmanandrenshaw.com/Conferences.
- ends -
For further information please contact:
Anne Bruinvels +44 (0) 20 7554 8790
CEO, Curidium Medica plc
Rob Smith +44 (0) 20 7554 8793
Finance Director, Curidium Medica plc
Rhodri Cruwys / Romil Patel +44 (0) 20 7448 4400
Blue Oar Securities plc
Billy Clegg / Edward Westropp / Anna Keeble + 44 (0)20 7831 3113
Financial Dynamics
About Homomatrix®
Homomatrix® is a fully automated analysis tool that uses proprietary
pattern recognition tools and sequences of mathematical algorithms
together with state-of-the-art statistical methods to objectively analyze
large sets of gene expression and biological data from heterogeneous
populations. These analyses can potentially lead to the development of
diagnostics that identify treatment-responsive patients and/or patient
subgroups, signalling pathways as well as drug targets. It is anticipated
that Homomatrix® could be of significant value in the drug development
arena where the "most likely to respond" patients could be pre-selected
to clinical trials.
About Curidium
Curidium is a company focused on identifying targeted medicines to treat
patients more effectively. Through the application of its proprietary
technology, Homomatrix®, Curidium analyses biological data (gene
expression/protein data) from patients suffering from complex or multi-
factorial diseases. Patient populations with complex disorders are known
to be heterogeneous and only certain subgroups of patients respond to a
specific treatment. Curidium believes that Homomatrix will ultimately
allow for the development of the right drug for the right patient. The
Company files patents around the genes and drug targets that are
associated with the specific subgroups of patients. Further information
on Curidium can be found at the Company's website:
www.curidium.com.
Curidium Medica plc (c) 2002-2007. All rights reserved.
Hamilton House, Mabledon Place, London WC1H 9BB, United Kingdom.
Email: info@curidium.com Tel.: +44 (0)20 7554 8790,
Fax: +44 (0)20 7554 8791
This information is provided by RNS
The company news service from the London Stock Exchange